Stifel Reiterates Buy Rating on AnaptysBio (ANAB)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- S&P 500, Nasdaq futures tick higher with Hormuz outlook in focus
- Oil edges higher as Iran tempers hopes of swift Hormuz reopening
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Atlassian results seen as 'game changer' for AI kills software worries
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
TD Cowen Reiterates Buy Rating on AnaptysBio (ANAB)
June 4, 2025 6:27 AM EDTTD Cowen analyst Joseph Thome reiterated a Buy rating on AnaptysBio (NASDAQ: ANAB).
The analyst comments "ANAB released updated data from the Ph. IIb of rosnilimab in RA. Rosnilimab patients that achieved LDA (CDAI10) continued to see benefit in the active... More
H.C. Wainwright Upgrades AnaptysBio (ANAB) to Buy
June 4, 2025 6:06 AM EDTH.C. Wainwright analyst Emily Bodnar upgraded AnaptysBio (NASDAQ: ANAB) from Neutral to Buy with a price target of $38.00.
The analyst comments "High maintenance of CDAI LDA and ACR responses, including during off-treatment period. Yesterday after market close, AnaptysBio announced anticipated Week 28 data from the Phase 2 rheumatoid arthritis (RA) trial which met its primary endpoint (announced in Feb 2025), evaluating rosnilimab 100 mg Q4W, 400 mg Q4W, or 600 mg Q2W vs placebo in 424 patients. As a reminder, to qualify to continue on treatment beyond the initial induction phase, patients must have had CDAI LDA... More
Anaptysbio (ANAB) Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
June 3, 2025 4:07 PM EDTAnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that investigational rosnilimab, a depleter and agonist targeting PD-1+ T cells, demonstrated a best-in-disease profile in patients with moderate-to-severe rheumatoid arthritis (RA). In the robust, global 424-patient Phase 2b trial, rosnilimab achieved JAK-like efficacy on multiple clinically meaningful measures, including low disease activity (LDA) and remission on the Clinical Disease Activity Index (CDAI), as well as ACR70 response, over a six-month period. Furthermore, responses were then durable for at least two months off drug. Rosnilimab was safe and well... More
